- About us
- Company details
Angiodroid is an italian innovative SME which develops, manufactures and markets medical devices. It is ISO 13485:2016 certified for the development and management of medical devices.
The Company has developed the first automatic injector for CO2 angiography (Angiodroid - The CO2 Injector), international distribuited in more than 50 countries, with more than 30 international market certifications.
Angiodroid was awarded by Deloitte (Fast EMEA 500) and won PGMX company prize in 2020.
The Company has also developed the first passive IABP consolle (Angiopulse consolle) and an innovative oxygen concentrator to support home therapy.
Year of establishment:
2014
Number of employees:
FROM 10 TO 19 EMPLOYEES
Annual turnover:
between 2.5 and 5 million Euro
Reference year of turnover:
2019
Export turnover:
0
Activities:
Manufacture of medical irradiation, electromedical and electrotherapeutic equipment
- Videos
- Catalogue
Angiodroid - Revolution of Innovation
Angiodroid Srl - Company Presentation
Angiodroid Brochure
- Contact Information
- Business Proposals
Company:
ANGIODROID SRL
Web site:
Address:
VIA CASELLE 76
City:
SAN LAZZARO DI SAVENA (BO)
Zip Code:
40068
E-commerce:
Social media:
Tag:
No business proposals uploaded
- Map
Angiodroid - The CO2 Injector
Angiodroid is the first unique automatic injector for peripheral angiography with CO2.
The injector let the user have a complete management of the gas dose and pressure of injection.
The system overcomes the issues related to air contamination, poor imaging and safety for the patients thanks to a patented technology which standardizes the use of CO2 in angiographic exams, reaching an excellent imaging technique in a shorter time.
The unit is portable, with a CO2 tank inside that ensures more than 500 procedures and it’s ready to inject in 6 seconds. Users can choose the parameters and then the injection can be started with touch screen, synchronizing the injector with the X-ray system, or wireless, with a dedicated remote control.
Dozens of scientific pubblications validated the use of the injector worldwide, and recent international guidelines suggested the use of automated CO2 angiography to save the renal function of patients.
The use of CO2 as a Contrast Agent can bring considerable advantages such as:
- no allergic reaction or no renal complications (avoid CIN risk);
- 20 times more soluble than O2 in the blood;
- 400 times less viscous than iodine (better endoleaks detection);
- fast and natural removal by normal breathing through lungs;
- cheap contrast
Angiodroid Srl has developed the first and unique automatic injector for CO2 management, that allows the physician to have complete control over the injection of the gas during the procedure. The injector has already obtained several certifications for commercialization in over 50 countries worldwide.
Find more at angiodroid.com
Documents